Printer Friendly

Garli-Eze delivers similar effects associated with fresh garlic.

A study presented at the Annual Meeting of the American College of Nutrition indicates that a new proprietary garlic product developed by Nutra Products, Inc. (Reno, NV), Garli-Eze, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yields no unsocial responses due to chewing fresh garlic.

Allicin is a very short-lived bioactive in garlic and thus requires sophisticated methods to measure its appearance. The study presented used a method developed by Dr. Larry Lawson, a world-renowned garlic researcher. This method employs a highly sensitive method of analyzing the breath after ingestion of garlic and unequivocally can determine if garlic was both delivered to the body for absorption, as well as its subsequent absorption.

The preliminary human study indicated that Garli-Eze could deliver large amounts of allicin directly to the upper gastrointestinal tract where it can be easily absorbed. Though it delivers as much natural allicin as fresh garlic, Garli-Eze does not contain offensive odors or discomfort. This new, all natural proprietary process is designed to eliminate the degradation of alliinase, which occurs when high potency garlic mixes with stomach acid. Garli-Eze activates in stomach acid yet doesn't use an "enteric coating," which typically employs a mix of synthetic chemicals designed to protect the capsule contents from stomach acid.

COPYRIGHT 2006 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH HIGHLIGHTS; Nutra Products, Inc
Publication:Nutraceuticals World
Article Type:Brief article
Geographic Code:1USA
Date:Nov 1, 2006
Previous Article:PectaSol Modified Citrus Pectin works well as oral chelator.
Next Article:High-ORAC bar.

Related Articles
Nutra Pharma Reports Successful Completion of ReceptoPharm's HIV In-Vitro Studies at Two Leading Universities.
Nutra Pharma Names Dr. Stewart Lonky to Board of Directors.
Nutra Pharma Names Former Revco and Eckerd Executive to Head New Medical Device Subsidiary.
Nutra Pharma Announces ReceptoPharm to Be a Featured Speaker at the 11th Annual Immunobiology Symposium.
Nutra Pharma Announces Publication of Research on Treatment for Multiple Sclerosis.
Nutra Pharma Announces Positive Results of ReceptoPharm Pain Study.
Nutra Pharma Announces Publication of Test Kit Technology in the International Journal of TB and Lung Diseases.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters